Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, July 2, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 1, 2025 the Company sold 500 (five hundred) repurchased own shares representing 0.0003% of the share capital of the Company, at a total value of BGN 3 600.00 on the Bulgarian Stock Exchange, the average price per share was BGN 7.20.
Sofia, Bulgaria, June 30, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 27, 2025 the Company sold 6 000 (six thousand) repurchased own shares representing 0.003% of the share capital of the Company, at a total value of BGN 39 760.00 on the Bulgarian Stock Exchange, the average price per share was BGN 6.63.
Sofia, Bulgaria, June 27, 2025 – In accordance with the requirements of art. 115c, para. 4 of LPOS “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the AGM of “Sopharma” AD that took place on June 27, 2025 regarding the type and amount of the voted dividend for 2024, the terms and conditions for its payment:
The General Meeting of Shareholders approved the proposal of the Board of Directors to distribute a gross dividend to shareholders in the amount of BGN 0.08 /eight stotinki/ per share.
Sofia, Bulgaria, June 26, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 26, 2025 the Company sold 3 511 700 (three million five hundred eleven thousand seven hundred) repurchased own shares representing 1.95% of the share capital of the Company, at a total value of BGN 22 966 639.00 on the Bulgarian Stock Exchange, the average price per share was BGN 6.54.